Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shaheen Alanee

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Urologic Oncology|January 3, 2016
Outcome of genetic evaluation of patients with kidney cancer referred for suspected hereditary cancer syndromesKelly L Stratton, Shaheen Alanee, Emily A Glogowski, et al.
Urologic Oncology|April 9, 2020
The effect of multiplicity of PI-RADS 3 lesions on cancer detection rate of confirmatory targeted biopsy in patients diagnosed with prostate cancer and managed with active surveillanceGrace Yaguchi, Hoang J Tang, Mustafa Deebajah, et al.
Histopathology|April 5, 2018
Pseudosarcomatous myofibroblastic proliferations of the genitourinary tract are genetically different from nodular fasciitis and lack USP6, ROS1 and ETV6 gene rearrangementsJudith A S Jebastin, Steven C Smith, Kyle D Perry, et al.
World Journal of Urology|May 9, 2021
Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatmentShaheen Alanee, Sherjeel Sana, Ahmed El-Zawahry, et al.
Cancer Medicine|May 22, 2019
Barriers to obtaining prostate multi-parametric magnetic resonance imaging in African-American men on active surveillance for prostate cancerEric L Walton, Mustafa Deebajah, Jacob Keeley, et al.
World Journal of Urology|August 3, 2018
Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladderShaheen Alanee, Isabel Alvarado-Cabrero, Paari Murugan, et al.
Cancers|July 29, 2025
[<sup>177</sup>Lu]Lu-PSMA-617 in Patients with Progressive PSMA+ mCRPC Treated With or Without Prior Taxane-Based Chemotherapy: A Phase 2, Open-Label, Single-Arm Trial in JapanKouji Izumi, Ryuji Matsumoto, Yusuke Ito, et al.
Urologic Oncology|August 25, 2018
Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysisPhilipp Gild, Stephanie A Wankowicz, Akshay Sood, et al.
European Urology|December 4, 2016
Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial CarcinomaThomas Seisen, Tarun Jindal, Patrick Karabon, et al.
Clinical Genitourinary Cancer|March 30, 2024
Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Guérin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guérin TreatmentJazzmyne Montgomery, Daniel Lybbert, Sherjeel Sana, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Urologic Oncology|January 3, 2016
Outcome of genetic evaluation of patients with kidney cancer referred for suspected hereditary cancer syndromesKelly L Stratton, Shaheen Alanee, Emily A Glogowski, et al.
Urologic Oncology|April 9, 2020
The effect of multiplicity of PI-RADS 3 lesions on cancer detection rate of confirmatory targeted biopsy in patients diagnosed with prostate cancer and managed with active surveillanceGrace Yaguchi, Hoang J Tang, Mustafa Deebajah, et al.
Histopathology|April 5, 2018
Pseudosarcomatous myofibroblastic proliferations of the genitourinary tract are genetically different from nodular fasciitis and lack USP6, ROS1 and ETV6 gene rearrangementsJudith A S Jebastin, Steven C Smith, Kyle D Perry, et al.
World Journal of Urology|May 9, 2021
Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatmentShaheen Alanee, Sherjeel Sana, Ahmed El-Zawahry, et al.
Cancer Medicine|May 22, 2019
Barriers to obtaining prostate multi-parametric magnetic resonance imaging in African-American men on active surveillance for prostate cancerEric L Walton, Mustafa Deebajah, Jacob Keeley, et al.
World Journal of Urology|August 3, 2018
Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladderShaheen Alanee, Isabel Alvarado-Cabrero, Paari Murugan, et al.
Cancers|July 29, 2025
[<sup>177</sup>Lu]Lu-PSMA-617 in Patients with Progressive PSMA+ mCRPC Treated With or Without Prior Taxane-Based Chemotherapy: A Phase 2, Open-Label, Single-Arm Trial in JapanKouji Izumi, Ryuji Matsumoto, Yusuke Ito, et al.
Urologic Oncology|August 25, 2018
Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysisPhilipp Gild, Stephanie A Wankowicz, Akshay Sood, et al.
European Urology|December 4, 2016
Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial CarcinomaThomas Seisen, Tarun Jindal, Patrick Karabon, et al.
Clinical Genitourinary Cancer|March 30, 2024
Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Guérin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guérin TreatmentJazzmyne Montgomery, Daniel Lybbert, Sherjeel Sana, et al.
Pageof 9